Long-Term Safety Study of Open-Label Pramipexole Extended Release (ER) in Patients With Early Parkinson's Disease (PD).

Trial Profile

Long-Term Safety Study of Open-Label Pramipexole Extended Release (ER) in Patients With Early Parkinson's Disease (PD).

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 15 Jun 2010 Actual number of patients added to 511 as reported by ClinicalTrials.gov.
    • 14 Jun 2010 Actual end date added to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 14 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top